Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EUA

- PMLiVE

FDA approves Incyte’s Opzelura for vitiligo

It is the first and only FDA-approved product for repigmentation in patients with nonsegmental vitiligo

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals

The report concluded that resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic

- PMLiVE

Elsevier launches global collaboration to ‘navigate’ changing landscape of scientific research

The initiative will examine the increased public attention on science during the COVID-19 pandemic and its impact on the academic research community

- PMLiVE

FDA grants Novavax’s COVID-19 vaccine emergency use authorisation for adults

The decision was based on data from a phase 3 trial which showed the vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19

- PMLiVE

NHS awarded George Cross for efforts shown during the COVID-19 pandemic

The George Cross is the UK’s highest civilian gallantry award and has only been given to a collective group twice before

- PMLiVE

Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally effective’ as mRNA vaccines

The study informs policymakers about the optimal deployment of COVID-19 vaccines over the next 12 months

- PMLiVE

UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

The new study by King’s College London found that the odds of experiencing long COVID were between 20-50% less during the Omicron period versus the Delta period

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

- PMLiVE

Pfizer’s Paxlovid given FDA permission to be prescribed by US pharmacists

Under the Emergency Use Authorisation revision, pharmacists will be able to prescribe the COVID-19 treatment to patients, providing they meet certain conditions

- PMLiVE

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

Lecanmab is being evaluated in the ongoing phase 3 Clarity Alzheimer's clinical trial

- PMLiVE

New Swiss research reveals how Omicron evades the immune system

A team from the University of Geneva and the Geneva University Hospital analysed the antibody neutralisation capacity of 120 people previously infected with one of the different COVID-19 variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links